Cite
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
MLA
Yamanaka, Yumie, et al. “Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.” Internal Medicine (Tokyo, Japan), vol. 56, no. 21, Nov. 2017, pp. 2895–98. EBSCOhost, https://doi.org/10.2169/internalmedicine.8638-16.
APA
Yamanaka, Y., Sekine, A., Kato, T., Yamakawa, H., Ikeda, S., Baba, T., Iwasawa, T., Okudela, K., & Ogura, T. (2017). Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity. Internal Medicine (Tokyo, Japan), 56(21), 2895–2898. https://doi.org/10.2169/internalmedicine.8638-16
Chicago
Yamanaka, Yumie, Akimasa Sekine, Terufumi Kato, Hideaki Yamakawa, Satoshi Ikeda, Tomohisa Baba, Tae Iwasawa, Koji Okudela, and Takashi Ogura. 2017. “Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.” Internal Medicine (Tokyo, Japan) 56 (21): 2895–98. doi:10.2169/internalmedicine.8638-16.